CClinicalTrials.gg
CompletedNCT04314609Updated Jun 18, 2020

Success Rate of Ultrasound Guided Sacroiliac Joint Injection in Sacroiliitis

An interventional study of Ultrasonography, fluoroscopy in Sacroiliitis, sponsored by Karim Alaaeldin Tawfik. Completed at 1 site in Egypt. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-06-18.

Sponsored by Karim Alaaeldin Tawfik · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
16 Years to 80 Years
Sex
All
01

Study summary

To re-investigate the success rate of Ultrasound guided sacroiliac joint steroid injection in depositing the drug inside the joint capsule (confirmed by contrast spread in fluoroscopy) and if there is a difference in clinical outcome between injections done strictly inside the joint and injections done periarticular.

Read the detailed description

An IV cannula will be inserted, and basic ASA monitors applied, then the patients will be positioned in prone position. After disinfection of the skin, Ultra sonography will be used to Guide Needle Placement in SIJ (the hypoechoic cleft between the surface of the sacrum and the ilium) under complete a sepsis as the technique previously described in the literature.

A low frequency (2-5 Hz) curvilinear transducer will be used in a sterile cover, the posterior superior iliac spine, lateral borderof sacrum, and ilium will be identified in transverse orientation. Subsequently, the probe will be moved caudally until the superior part of the posterior SIJ is identified. The SIJ will be traced caudally until the distal third of the SIJ is visualized as evident by the flat contour of the iliac crest and the presence of the second sacral foramen on the medial aspect of the sacrum.

After local anesthetic infiltration of skin and subcutaneous tissues using Lidocaine 1%, a 21-gauge spinal needle will be advanced from a medial to lateral direction using an in-plane technique. After reaching the joint, a total volume of 4 ml of injectate will be injected which consists of: 1 ml 40 mg of methylprednisoloneacetate (Depo-Medrol®, Pfizer), 2 ml Lidocaine 2%, 1 ml Iohexol (Omnipaque 300®, GE Healthcare).

Control fluoroscopy

After injection of the drug and withdrawal of the needle, a antero-posterior fluoroscopy image will be obtained and recorded for the injected joint to detect the spread pattern of the contrast and whether its pre-dominantly intra or periarticular. (N.B: Periarticular injection is any injection done near the joint as evidenced by US but on fluoroscopy no contrast is detected inside the joint). Then a sterile patch will be applied to the puncture site and patient discharged to the recovery room for follow-up for 30 minutes before discharge to home.

Measurement tools

  • Total number of intraarticular and periarticular drug injections as evidenced by contrast spread in fluoroscopy.
  • Patient's pain score rated from 0-10 (Numeric Pain Rating Scale, NRS) before the procedure, 10 minutes after the procedure (in the recovery room), 1 week and 1 month post-procedure.
  • Demographic data (including age, sex, BMI, ASA score).
  • Limitation of physical functioning as measured by the Oswestry Disability Index (ODI) at 1 month after the procedure .
  • Procedure-related variables (time, complications, patient satisfaction.
02

Conditions studied

  • Sacroiliitis

Browse trials for

03

Who can participate

Ages eligible
16 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Subject has sacroiliitis (acute or chronic) by history.
  • Failed conservative therapy eg. bed rest, anti-inflammatory medications and physical therapy for at least 6 weeks.

Exclusion criteria

Exclusion Criteria:

  • Subject has BMI above 35 kg/m2
  • Coagulopathy.
  • Renal or Hepatic Failure.
  • Current Pregnancy or actively pursuing pregnancy.
  • Known allergy to local anesthetic or steroids.
  • Infection at site of needle placement or SIJ infection.
  • Prior surgical procedures involving the SIJ.
  • Previous surgical Fixation involving the lumbar spine.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Ultrasound , fluroscope

    After injection of corticosteroids with 1 ml contrast in sacroiliac joint using ultrasound and withdrawal of the needle, an antero-posterior fluoroscopy image will be obtained and recorded for the injected joint to detect the spread pattern of the contrast and whether its pre-dominantly intra or periarticular.

    Device: Ultrasonography, fluoroscopy

Interventions

  • DeviceUltrasonography, fluoroscopy

    success rate of Ultrasound guided SIJ steroid injection confirmed by contrast spread in fluoroscopy

05

What researchers measure

Primary outcomes

  1. success rate of ultrasound sacroiliac joint injection

    Percent of successful intraarticular drug injections during USG SIJ steroid injection (as confirmed by contrast spread in fluoroscopy)

    Time frame: Immediately after injection

Secondary outcomes

  1. Difference in clinical outcome between intraarticular and periarticular injections.

    Difference in clinical outcome between intraarticular and periarticular injections (confirmed via fluroscopy) as measured clinically by numerical pain score (NPS is a scale from 0 to 10. 0 is no pain and 10 is the maximum pain)

    Time frame: After 10 minutes, 1 week and 1 month

  2. Clinical improvement

    Pain score at 10 minutes , 1 week and 1 month after intervention by numerical pain score (NPS is a scale from 0 to 10. 0 is no pain and 10 is the maximum pain)

    Time frame: After 10 minutes, 1 week ,1 month

06

Study locations

1 site
  • Faculty of medicine cairo university
    Cairo, 11562, Egypt
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04314609
Lead sponsor
Karim Alaaeldin Tawfik
Responsible party
Karim Alaaeldin Tawfik (Doctor, Cairo University) — Sponsor-investigator
First posted
Mar 19, 2020
Start date
Oct 1, 2019
Primary completion
May 1, 2020
Completion
Jun 1, 2020
Last update
Jun 18, 2020

Study contacts

Amany E Ayad, M.D
principal investigator · Cairo University
Ahmed Z Fouad, M.D
study chair · Cairo University
Mohamed A Mansour, M.D
study chair · Cairo University
Karim A Tawfik, MSc
study chair · Cairo University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion